MNCs Step Up Competition For China Tumor Drug Market
This article was originally published in PharmAsia News
At the recent annual meeting of the American Society for Clinical Oncology, Bayer HealthCare released the Asia Pacific clinical trial results of its new drug Nexavar (sorafenib). This tumor drug represents the company's first to have its R&D conducted specifically for populations in China and Asia Pacific. Bayer officials say that due to China's huge potential in the tumor drug market, future product trials will consider Chinese patients and, if required, exclusive clinical tests will be carried out. Tumor drugs make up the fastest-growing segment within China's pharmaceutical market, spurring global drug giants to bring their latest offerings into the country. Nexavar was introduced to China only three months after it gained FDA approval in 2006. (Click here for more - Chinese Language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.